Cargando…
Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma
BACKGROUND: Metastatic melanoma is an aggressive skin cancer with a poor prognosis. Current treatment strategies for high-stage melanoma are based around the use of immunotherapy with immune checkpoint inhibitors such as anti-PDL1 or anti-CTLA4 antibodies to stimulate anti-cancer T cell responses, y...
Autores principales: | De Santo, Carmela, Cheng, Paul, Beggs, Andrew, Egan, Sharon, Bessudo, Alberto, Mussai, Francis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960181/ https://www.ncbi.nlm.nih.gov/pubmed/29776373 http://dx.doi.org/10.1186/s13045-018-0612-6 |
Ejemplares similares
-
The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated‐recombinant arginase I BCT‐100
por: De Santo, Carmela, et al.
Publicado: (2017) -
Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies
por: Fultang, Livingstone, et al.
Publicado: (2021) -
Targeting the arginine metabolic brake enhances immunotherapy for leukaemia
por: Mussai, Francis, et al.
Publicado: (2019) -
Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma: The role of Arginase 2 in sorafenib-induced ferroptosis in melanoma
por: Yu, Yi, et al.
Publicado: (2022) -
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
por: Fultang, Livingstone, et al.
Publicado: (2019)